NanoSphere Health Sciences (CSE:NSHS) is pleased to announce the Company has signed a Definitive Master Licensing Agreement (the Agreement) with Delta 9 Cannabis Inc. (TSXV: NINE) (OTC: VRNDF) (Delta 9) in a deal that opens the Canadian market to NanoSphere’s patented groundbreaking delivery technology.

NanoSphere’s wholly-owned, Canadian-based subsidiary, NanoSphere Cannabis International Inc. (NCI).helped facilitate the agreement and assisted Delta 9 with the first product submission to Health Canada which has now received preliminary approval.


Recently awarded U.S. Patent No. 10,028,919, NanoSphere has been granted market exclusivity over the standardized delivery of cannabis through phospholipid nanoparticle technology. The new patent granted last year complements NanoSphere’s previously issued patent, U.S. Patent No. 9,925,149, covering the core technology behind the production of the NanoSphere Delivery System™.

The Agreement grants Delta 9 an exclusive Master License to manufacture and sell products made with Nanosphere’s patented technology. The two companies have begun working on the first product for Canada; an intraoral cannabis oil under the Company’s Evolve Formulas brand containing cannabinoid nanoparticles, that is being produced over the next month for an upcoming inspection for final approval by Health Canada.

“This partnership with Delta 9 represents an ongoing phase of growth for NanoSphere Health” said Robert Sutton, Chairman and CEO of NanoSphere Health Sciences. “We are proud to offer the first and only patented cannabinoid delivery system for a safer, more effective method of consumption to the Canadian market.”

“This agreement with Delta 9 marks a critical inflection point in NanoSphere’s development, allowing our entry into the world’s most developed cannabis market,” said NCI President Gary Symons.“

NanoSphere’s groundbreaking delivery system works by nano-encapsulating active ingredients in phospholipid membranes for transportation through the skin and mucosa into the bloodstream within minutes. Cannabis applications of the technology into intraoral products will provide rapid results, precise dosages and high bioavailability. This cutting-edge advancement eliminates the need for inhalation or ingestion of cannabis, offering users a safer and more effective method of consumption.

Delta 9 CEO John Arbuthnot says the agreement paves the way for an entirely new form of consumption for both medical and recreational consumers of cannabis.

“On the recreational side, we can now provide a healthier alternative to smoking or vaping cannabis, but that still gives you the same or better effect,” said Arbuthnot. “Equally important, our NanoSphere products provide for the first time a truly appropriate way to deliver medical cannabis, with precise dosage, better bio-availability, and without essentially having to ‘smoke your medicine’.”

Under the agreement, Delta 9 will pay to NanoSphere a Licensing Fee of $500,000 Cdn. while NanoSphere will equip the production lab and train Delta 9 staff in the production of the Evolve Formulas product line. Delta 9 and NanoSphere will each receive 50 percent of the gross profit from the sale of Evolve Formulas products. The initial term of the agreement is 36 months following the date of the first commercial sale of licensed products.

NanoSphere’s Commitment to Licensing IP

NanoSphere launched its IP licensing program in 2015 and is entertaining several licensing opportunities via a rigorous evaluation process. For more information about NanoSphere’s licensing program, please visit: https://www.nanospherehealth.com/licensing/

About NanoSphere

NanoSphere Health Sciences LLC, is a biotechnology firm specializing in the creation of the NanoSphere Delivery System™, a revolutionary platform using nanotechnology in the biodelivery of supplements, nutraceuticals and over-the-counter medications for the cannabis, pharmaceutical and animal health industries, and beyond. For more information on NanoSphere, please visit http://www.nanospherehealth.com.

About Evolve Formulas

Evolve Formulas is the provider of the world’s first and only scientifically proven nanoparticle delivery system in cannabis. Evolve’s pioneering product, Transdermal NanoSerum™, is a fast-acting, ultra-strength transdermal formula infused with nano-encapsulated cannabis and cannabis extracts. NanoSerum™ immediately penetrates the skin to deliver direct-focused results and intelligently carries a full spectrum of cannabinoids and phytochemicals to receptors throughout the body for systemic healing. For more information on Evolve Formulas, visit https://www.evolveformulas.com/. Follow us on FacebookInstagram and Twitter.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statement Caution

This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company’s intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company’s future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Without limitation, these include assumptions, risks and uncertainties inherent in completing sub-licensing arrangements in the United States, Canada and abroad, product demand, production, competition and government regulation of the Cannabis industry, any and all of which may have an adverse effect on the Company’s expansion plans, sales, revenues and its financial results and condition.Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

logo

Contacts

On behalf of the Board
Robert E Sutton, Chairman
NanoSphere Health Sciences Inc.
720-845-1483
Rsutton@nanospherehealth.com

Investor Contact:
Gary Symons President
NanoSphere Cannabis International, Inc.
Mobile: 250-300-9352
E-mail: Gsymons@nanospherehealth.com

Click here to connect with NanoSphere Health Sciences (CSE:NSHS) for an Investor Presentation. 

Source: business.financialpost.com

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less